Clinical Trial Update: Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with capecitabine for locally advanced or metastatic triple-negative breast cancer or hormone-refractory breast cancer th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Hormone-refractory Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Northwestern University | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Status: UNKNOWN | Results posted: 2020-07-13